Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by QualityTeston Dec 01, 2020 11:25am
114 Views
Post# 32009487

RE:RE:RE:RE:My goodness..

RE:RE:RE:RE:My goodness..J4P,

Phase 3 won't be swapped out for Phase IV, regardless of (if) who we partner with. RVX said they would push for approval with the FDA in one of their PR's (maybe last year's AGM) and they acknowledged it would be a long shot. If the FDA was at all open to that idea, we would have heard about it when we got the update about how RVX's meeting with the FDA went, imo.

Agree that BP's need to replenish their pipelines, but they have one big advantage: $$ so they can wait to get the deal that they want. We need them more than they need us.

BP's these days are much less into taking risk and prefer to pay more for a sure thing. That's at least why I think a partnership with a ROFR for a BP so they get first kick at the can after BoM2.
<< Previous
Bullboard Posts
Next >>